Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2008
07/03/2008US20080161313 7-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dimethylbenzyl)amide; retin inhibitor with other active ingredients; cardiovascular diseases and renal insufficiency
07/03/2008US20080161312 Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications
07/03/2008US20080161311 e.g. 2-(3,4-dichlorobenzyl)-9-hydroxy-3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,8-dione hydrochloride; AIDS, or as an anti-HIV agent; non-toxic, fewer side effects
07/03/2008US20080161310 (2S)-4,4-difluoro-1-(2-{[1-(2-pyrazinyl)piperidin-4-yl]amino}acetyl)-2-pyrrolidine carbonitrile; enzyme inhibitors; diabetes
07/03/2008US20080161309 Novel Compounds
07/03/2008US20080161308 e.g. 4-[6-(2-cyclohexylethoxy)-3-oxoindan-5-yloxy]butanoic acid; peroxisome proliferator-activated receptor (PPAR) gamma agonist; antiinflammatory, antidiabetic agent; dyslipidaemia, atherosclerosis, insulin resistance
07/03/2008US20080161307 Organic Compounds
07/03/2008US20080161306 Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors
07/03/2008US20080161305 C-Met Modulators and Methods of Use
07/03/2008US20080161304 e.g. 1'-(1-Benzothien-2-ylcarbonyl)-3H-spiro[2-benzofuran-1,4'-piperidine]; vasopressin receptor antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder
07/03/2008US20080161303 Imidazo- and triazolo-pyridine compounds and methods of use thereof
07/03/2008US20080161302 Antifungal Agents
07/03/2008US20080161301 2-Oxy-Benzoxazinone Derivatives for the Treatment of Obesity
07/03/2008US20080161300 Heterobicyclic metalloprotease inhibitors
07/03/2008US20080161299 6'-Bromo-1-[(5-methoxy-3-methyl-1H-indol-2-yl)carbonyl]-1'H-spiro[piperidine-4,4'-quinolin]-2'(3'H)-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder
07/03/2008US20080161298 Spiro-piperidine derivatives
07/03/2008US20080161297 Rho kinase inhibitors
07/03/2008US20080161296 Nebivolol and a cardiovascular agent; hypertension
07/03/2008US20080161295 e.g. 3-(2,2-dioxido-1-phenyl-1,4-dihydro-3H-2,1,3-benzothiadiazin-3-yl)-N-methylpropan-1-amine; monoamine reuptake inhibitors; antidepressant, anxiolytic, anticarcinogenic, antiinflammatory, antidiabetic agent; hyperactivity, sleep disturbance, social phobia, chronic fatigue syndrome, viral infection
07/03/2008US20080161294 Urea derivative, medicinal composition containing the same, and medicinal use of these
07/03/2008US20080161293 Antitumor Agent
07/03/2008US20080161292 Inhibitors of poly(adp-ribose)polymerase
07/03/2008US20080161291 Antineoplastic agents
07/03/2008US20080161290 Serine hydrolase inhibitors
07/03/2008US20080161289 6-Cyclobutyl-2-[4-(trifluoromethyl)phenyl]-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[4,5-d]azepine; neurological and psychiatric disorders
07/03/2008US20080161288 e.g. 7-hydroxy-6-{(1R*)-[3-(4-hydroxyphenyl)-1-methylpropyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; beta-2 adrenoceptor agonist; as a teed additive for a livestock animal as poultry and birds; veterinary medicine
07/03/2008US20080161287 Bicyclic compound, production and use thereof
07/03/2008US20080161286 excellent purity; bradycardic agent; myocardial ischaemia: angina pectoris, myocardial infarct, arrhythmia disturbances, heart failure; structure confirms by X-ray diffraction data; industrial scale, storage stability
07/03/2008US20080161285 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
07/03/2008US20080161284 excellent purity; bradycardic agent; myocardial ischaemia: angina pectoris, myocardial infarct, arrhythmia disturbances, heart failure; structure confirms by X-ray diffraction data; industrial scale, storage stability
07/03/2008US20080161282 Cytotoxic agents and methods of use
07/03/2008US20080161281 Amino-Substituted Tricyclic Derivatives and Methods of Use
07/03/2008US20080161280 Inhibitors of poly(adp-ribose)polymerase
07/03/2008US20080161279 Methods of Treating Obesity
07/03/2008US20080161278 2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
07/03/2008US20080161277 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
07/03/2008US20080161276 Monoacyl lipid, diacyl glycerol, tocopherol, and fragmentation agent; capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid; controlled-release formulations and for solubilising relatively insoluble compounds
07/03/2008US20080161275 Compositions and methods for the treatment of inflammatory disease
07/03/2008US20080161274 Compounds and methods for inhibition of bone loss
07/03/2008US20080161273 Method of Using Adapalene in Acne Maintenance Therapy
07/03/2008US20080161272 Ceramide derivatives, method for preparing the same, and therapeutic agent for treating atopic dermatitis comprising the ceramide derivatives
07/03/2008US20080161271 e.g. 9-Hydroxy-2-(2-methoxy-ethyl)-1,8-dioxo-1,8-dihydro-2H-pyrid[1,2-a]pyrazi ne-7-carboxylic acid 4-fluoro-banzylamide; Human T cell leukemia virus, Feline and Simian immunodeficiency virus inhibitor; side effects reduction
07/03/2008US20080161270 Angiogenesis inhibitors
07/03/2008US20080161269 Compounds 620
07/03/2008US20080161268 Quaternary ammonium salt antibacterial and water-borne coating material having antibiotic property containing the same
07/03/2008US20080161267 Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants
07/03/2008US20080161266 Aqueous solution of alginate having guluronic units bound to an adjacent guluronic unit as a percentage of the total number of monomeric units and a cationic antimicrobial agent; forms less deactivating complexes with cationic antimicrobial agent
07/03/2008US20080161265 Use of lactulose in the treatment of autism
07/03/2008US20080161264 N-{3-[3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-exo-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}-4,4-difluorocyclohexanecarboxamide; with deuterium isotop; chemokine (C-C motif) CCR5 receptor antagonist; antiinflammatory agent, viricide; with other active ingredients; HIV, AIDS, multiple sclerosis
07/03/2008US20080161263 Fusion proteins of Mycobacterium tuberculosis
07/03/2008US20080161262 Using oligonucleotide sequences specific to interleukin beta as blocking agents for treatment and prevention of juvenile idiopathic arthritis
07/03/2008US20080161261 Defective sindbis viral vectors
07/03/2008US20080161260 Contacting the genomic DNA with monoclonal anti-HdU antibodies; contacting the anti-HdU antibodies bound to the HdU-containing DNA with a compound that is converted to a light-emitting product; determining the intensity of the chemiluminescent signal
07/03/2008US20080161259 Complementary to a target nucleotide sequence; reduces the expression and/or function of the target nucleotide sequence; antiinflammatory
07/03/2008US20080161258 Hsp and Supraventricular Arrhythmia
07/03/2008US20080161257 Oligonucleotide-Containing Pharmacological Compositions And Their Use
07/03/2008US20080161256 Treating Hepatitis B Virus (HBV) with Adefovir Dipivoxil in combination with a chemically synthesized double stranded nucleic acid; toxicologic properties while retaining RNAi activity
07/03/2008US20080161255 Use of Parp Inhibitors for Prevention and Treatment of Diabetic and Insulin Resistance Complications
07/03/2008US20080161254 Hcv inhibitors
07/03/2008US20080161253 Composition for the treatment of nasopharyngeal carcinoma and method of use thereof
07/03/2008US20080161252 (E)-2-(5-((2,4,6-trimethoxystyrylsulfonyl)methyl)-2-methoxyphenylamino)acetic acid; antiproliferative; anticarcinogenic agent : solid tumors, leukemia; "cytoproliferative" diseases: atherosclerosis, fibrosis, Paget's disease; synergistic effect with other active ingredients
07/03/2008US20080161251 Combination of a cytotoxic agent such as gemcitabine and a compound that inhibits cyclin dependent kinase (CDK) and/or glycogen synthase kinase (GSK, e.g. GSK-3) such as 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide
07/03/2008US20080161250 Topical treatment or prevention of ocular infections
07/03/2008US20080161249 Use of Novel Antibacterial Compounds
07/03/2008US20080161248 Methods and Compositions for Therapeutic Treatment
07/03/2008US20080161247 Synergistic composition for modulating activity of substrate analogs for NAD+, NADP+, NADH or NADPH dependent enzymes and process thereof
07/03/2008US20080161241 Preventing sustained monomorphic ventricular tachycardia following myocardial ischemia by administering etanercept; or bortezomib; inhibits substantial loss of beta-adrenergic receptor kinase (beta-ARK) activity
07/03/2008US20080161240 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
07/03/2008US20080161231 Methods and compositions for promoting organ development
07/03/2008US20080161228 Using metabolomics to expedite drug discovery and development; invention provides means to select and advance most selective lead compounds from series of candidates based on metabolomic profiles which contain data regarding both expected or intended (e.g., on-target) and unexpected effects of compounds
07/03/2008US20080160613 Nonhuman model animal lacking the ability to control lymphocyte migration
07/03/2008US20080160552 Methods and Compounds for Treating Inflammation
07/03/2008US20080160120 Lapactic agent
07/03/2008US20080160119 Sesquiterpenoid Derivatives Having Adipocyte Differentiation Inhibitory Effect
07/03/2008US20080160116 Compositions and Methods Comprising Zingiber Species
07/03/2008US20080160110 Anti-Aging Cosmetic Composition
07/03/2008US20080160108 Method of treating muscular dystrophies with an inhibitor of histone deacetylase
07/03/2008US20080160106 Novel Uses for Proton Pump Inhibitors
07/03/2008US20080160105 Administration of 2-methoxyestradiol or it derivatives such as colchicine or combretastatin A-4; for treating and/or preventing a pregnancy related disease; safer and more effective
07/03/2008US20080160101 Composition For Use Against One Or More Pathogens
07/03/2008US20080160099 Methods For Treating or Preventing a Vascular Disease
07/03/2008US20080160095 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
07/03/2008US20080160094 Comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein; brain disorders; kits; efficiently target and deliver substances
07/03/2008US20080160093 Composition comprising particulate zinc materials having a defined crystallite size
07/03/2008US20080160087 Gel preparation for oral administration
07/03/2008US20080160082 Controlled release compositions comprising Nimesulide
07/03/2008US20080160081 Release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP; benign prostatic hyperplasia, lower urinary tract symptoms, female sexual dysfunction, premature ejaculation, and primary dysmenorrheal
07/03/2008US20080160080 comprising 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide and a stabilizing polymer; prepared by dissolving drug and stabilizing polymer in a solvent to form a feed solution and then spray drying the feed solution to form amorphous solid dispersion as a powder
07/03/2008US20080160076 consist of water-insoluble hydrophobic synthetic materials which do not significantly affect the pharmaceutical quality of the contents themselves, but improve usability of filled capsules with regard to function, longevity, and/or the geographic location of their use
07/03/2008US20080160074 three-dimensional synthetic and semi-synthetic compositions having biological activity, such as liposomes, beads or similar particles; anti-inflammatory, organ protective and immune regulatory effects
07/03/2008US20080160070 fabric backing and a skin-adhesive polymer matrix; compound diffuses from the matrix through the stratum corneum layer of the user's skin, through the dermis layer of the skin, and into the user's bloodstream
07/03/2008US20080160067 high bioavailability; comprising an antibiotic, a hydrophobic material, soy protein fines, a disintegrant, a solvent, and optionally a flavor
07/03/2008US20080160066 lecithin-DHA-type phospholipid; treating or preventing respiratory failure
07/03/2008US20080160065 insert suitable for mammalian intravaginal, buccal, or intrarectal use; non-degradable hydrogel matrix
07/03/2008US20080160063 particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks
07/03/2008US20080160061 stent having a protein patterning or bioactive patterning; contains a protein and an agent selected from an adhesion molecule including an RGD motif, a chemo-attractant of an endothelial cell, a NO releasing or generating material or agent, an agent that promotes endothelialization, or combinations
07/03/2008US20080160060 administering locally a therapeutic amount of a Sost/Wise antagonist in conjunction with an osteoconductive biocompatible calcium salt scaffold; medical orthopedic or periodontal device; prevents kidney damage
07/03/2008US20080160058 bait and uses thereof
07/03/2008US20080160054 vectors or transgenic organisms; biosynthesis; derived from Physcomitrella
07/03/2008US20080160048 Comprising chimeric cytomegalo virus related promoter sequence and cloning site for insertion of coding sequence in operable linkage; particle mediated gene therapy and immunization